Headquarters California, United States | Founded 1998 | |
 | ||
Stock price IMMY (NASDAQ) US$ 2.47 -0.02 (-0.80%)10 Mar, 4:00 PM GMT-5 - Disclaimer CEO Mark L. Baum Esq. (Dec 2011–) Subsidiaries South Coast Specialty Compounding, Inc., Pharmacy Creations, LLC, JT Pharmacy, Inc., ImprimisRx PA, Inc. | ||
Imprimis Pharmaceuticals is a publicly traded pharmaceutical company (NASDAQ: IMMY) based in San Diego. It makes eye drops, compounded medicines and other products.
It manufactures a pyrimethamine and leucovorin compound which may offer a low-cost "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000% by Martin Shkreli and Turing Pharmaceuticals.
Governance
In October 2015, Anthony Principi was elected to the company's board of directors.
References
Imprimis Pharmaceuticals Wikipedia(Text) CC BY-SA